Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAD Followed by Thal/Dex in Relapsed/Refractory Multiple Myeloma
NCT00319865Phase 2Unknown
- Start
- Nov 2005
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and thalidomide in multiple myeloma (MM). Primary endpoint: Response rate of PAD induction Therapy. Status: unknown.
02
Drugs
bortezomibthalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00319865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00319865.